Ifosfamide in testicular cancer.
Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.
Loehrer
P J
PJ
Department of Medicine, Indiana University School of Medicine, Indianapolis.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide